NCT03773107 · OUTCOME

Duration of Response

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma · Source last updated 2025-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: Full Range
Time frame: approx. 5 years

What was measured

Duration of response will be defined as the time from first objective status assessment of response to the time of first documented disease progression or death.

Analysis population: Duration of best response calculated only for participants who achieved a PR or better.

Groups in this outcome

Phase I 5mg Ruxolitinib

Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 10 mg Ruxolitinib

Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 15mg Ruxolitinib

Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Phase I 5mg Ruxolitinib	0
Phase I 10 mg Ruxolitinib	2
Phase I 15mg Ruxolitinib	1

Reported measurements

Source class 1

Values in months · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Phase I 10 mg Ruxolitinib	4.8	Not reported	2.2	7.4	Not reported
Phase I 15mg Ruxolitinib	8.5	Not reported	8.5	8.5	Not reported

Complete source fields

classes

categories
measurements
group Id
OG001
lower Limit
2.2
upper Limit
7.4
value
4.8
group Id
OG002
lower Limit
8.5
upper Limit
8.5
value
8.5

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
2
group Id
OG002
value
1
units
Participants

description

Duration of response will be defined as the time from first objective status assessment of response to the time of first documented disease progression or death.

dispersion Type

Full Range

groups

description
Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
id
OG000
title
Phase I 5mg Ruxolitinib
description
Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
id
OG001
title
Phase I 10 mg Ruxolitinib
description
Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
id
OG002
title
Phase I 15mg Ruxolitinib

param Type

MEDIAN

population Description

Duration of best response calculated only for participants who achieved a PR or better.

reporting Status

POSTED

time Frame

approx. 5 years

title

Duration of Response

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice